This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
kawasaki disease | 1270 |
coronary artery | 308 |
kawasaki syndrome | 119 |
clinical features | 114 |
kd patients | 113 |
mg kg | 91 |
inflammatory syndrome | 83 |
acute phase | 82 |
shock syndrome | 78 |
intravenous immunoglobulin | 77 |
multisystem inflammatory | 74 |
coronavirus disease | 71 |
fi ndings | 70 |
coronary arteries | 66 |
incomplete kd | 65 |
infl ammatory | 65 |
infl ammation | 63 |
immune response | 61 |
viral infections | 59 |
artery abnormalities | 58 |
immune cells | 56 |
immune system | 55 |
ivig treatment | 55 |
acute respiratory | 54 |
like disease | 53 |
artery lesions | 51 |
kg day | 51 |
toxic shock | 48 |
neonatal lupus | 47 |
respiratory tract | 46 |
heart disease | 45 |
united states | 45 |
severe acute | 44 |
may also | 44 |
endothelial cells | 43 |
respiratory syndrome | 43 |
fi rst | 43 |
en el | 42 |
systemic vasculitis | 41 |
lupus erythematosus | 41 |
gut microbiota | 41 |
disease kawasaki | 40 |
kd cases | 40 |
nervous system | 39 |
pediatric patients | 38 |
cord uid | 38 |
doc id | 38 |
acute febrile | 38 |
cervical lymphadenopathy | 37 |
central nervous | 37 |
reactive protein | 37 |
defi ciency | 35 |
increased risk | 35 |
severe covid | 34 |
respiratory symptoms | 34 |
respiratory viruses | 33 |
human coronavirus | 33 |
acute kawasaki | 32 |
clinical manifestations | 32 |
lymph node | 32 |
infectious diseases | 31 |
case report | 31 |
inflammatory markers | 31 |
rheumatic fever | 31 |
erythema multiforme | 31 |
ivig infusion | 31 |
innate immune | 31 |
syndrome coronavirus | 30 |
abdominal pain | 30 |
clinical course | 30 |
coronary aneurysms | 30 |
may occur | 30 |
coronary arteritis | 30 |
vessel vasculitis | 29 |
artery aneurysms | 29 |
cytokine storm | 29 |
sedimentation rate | 29 |
american heart | 29 |
barr virus | 28 |
conjunctival injection | 28 |
congenital heart | 28 |
immune complexes | 28 |
erythropoietic porphyria | 28 |
cell arteritis | 28 |
heart association | 28 |
diagnostic criteria | 28 |
infectious agents | 28 |
virus infection | 28 |
pediatric covid | 28 |
kd may | 27 |
ks patients | 27 |
clinical characteristics | 27 |
giant cell | 27 |
wide association | 27 |
necrosis factor | 27 |
congenital erythropoietic | 27 |
peripheral blood | 27 |
polyarteritis nodosa | 27 |
novel coronavirus | 27 |
erythrocyte sedimentation | 27 |
heart block | 26 |
heart failure | 26 |
may lead | 26 |
term management | 26 |
laboratory findings | 26 |
staphylococcus aureus | 26 |
persistent fever | 25 |
node syndrome | 25 |
clinical symptoms | 25 |
strawberry tongue | 25 |
acquired heart | 25 |
antineutrophil cytoplasmic | 25 |
young children | 25 |
viral infection | 24 |
pathogenic proteins | 24 |
oral cavity | 24 |
health professionals | 24 |
concomitant infection | 24 |
sin embargo | 24 |
infectious disease | 24 |
risk factors | 24 |
concurrent infection | 24 |
macrophage activation | 24 |
endothelial cell | 24 |
significantly higher | 24 |
mucocutaneous lymph | 23 |
artery aneurysm | 23 |
inflammatory cytokines | 23 |
purpura fulminans | 23 |
infectious agent | 23 |
ivig non | 23 |
tumor necrosis | 23 |
immune responses | 23 |
cardiovascular disease | 23 |
infi ltrate | 23 |
activation syndrome | 22 |
ivig resistance | 22 |
case series | 22 |
intensive care | 22 |
platelet count | 22 |
immunofl uorescence | 22 |
acute kd | 22 |
urticarial vasculitis | 21 |
bcg reactivation | 21 |
differential diagnosis | 21 |
aso titer | 21 |
refractory kawasaki | 21 |
initial treatment | 21 |
clinical presentation | 21 |
refractory kd | 21 |
chain reaction | 20 |
initial ivig | 20 |
febrile mucocutaneous | 20 |
heat shock | 20 |
prolonged fever | 20 |
converting enzyme | 20 |
imaging findings | 20 |
vessel wall | 20 |
respiratory distress | 20 |
higher risk | 20 |
skin lesions | 20 |
association study | 20 |
systemic inflammation | 20 |
polymerase chain | 20 |
informed consent | 19 |
annular erythema | 19 |
measles virus | 19 |
susceptibility loci | 19 |
disease may | 19 |
blood vessels | 19 |
adaptive immune | 19 |
genetically susceptible | 19 |
among patients | 19 |
immune complex | 19 |
skin rash | 19 |
growth factor | 19 |
associated vasculitis | 19 |
dose aspirin | 19 |
white blood | 19 |
upper respiratory | 19 |
incomplete kawasaki | 19 |
systemic infl | 19 |
true clusters | 18 |
among children | 18 |
respiratory viral | 18 |
gamma globulin | 18 |
common cause | 18 |
pityriasis rosea | 18 |
cell activation | 18 |
disease shock | 18 |
resistant kawasaki | 18 |
type i | 18 |
acute stage | 18 |
immune globulin | 18 |
years old | 18 |
gene polymorphisms | 18 |
clinical criteria | 18 |
scarlet fever | 18 |
developed countries | 17 |
many patients | 17 |
temporally associated | 17 |
etiologic agent | 17 |
cohort study | 17 |
severe disease | 17 |
plasma cells | 17 |
immune activation | 17 |
incidence rates | 17 |
early childhood | 16 |
second dose | 16 |
lymph nodes | 16 |
immunoglobulin treatment | 16 |
atypical kawasaki | 16 |
new york | 16 |
disease patients | 16 |
infi ltrates | 16 |
schonlein purpura | 16 |
streptococcal infection | 16 |
en los | 16 |
risk factor | 16 |
vascular endothelial | 16 |
skin biopsy | 16 |
temporal artery | 16 |
th day | 16 |
myocardial infarction | 16 |
outpatient clinic | 16 |
cell receptor | 16 |
mg dl | 16 |
strauss syndrome | 16 |
erythropoietic protoporphyria | 16 |
respiratory failure | 16 |
intravenous gamma | 16 |
syndrome temporally | 16 |
significant association | 16 |
class ii | 16 |
disease association | 16 |
diffi cult | 15 |
cytoplasmic antibodies | 15 |
coronary arterial | 15 |
disease associated | 15 |
fl uid | 15 |
cytokine production | 15 |
severe clinical | 15 |
fever duration | 15 |
affected children | 15 |
inoculation site | 15 |
inflammatory multisystem | 15 |
tissue injury | 15 |
blood cell | 15 |
novel human | 15 |
principal clinical | 15 |
streptococcus pyogenes | 15 |
homozygous protein | 15 |
annulare centrifugum | 15 |
prospective study | 15 |
sweet syndrome | 15 |
erythema annulare | 15 |
takayasu arteritis | 15 |
multisystem syndrome | 15 |
type ii | 15 |
coronavirus infection | 15 |
giant cells | 15 |
receptor antagonist | 15 |
natriuretic peptide | 15 |
fi nding | 15 |
phase reactants | 15 |
signi fi | 15 |
syndrome kawasaki | 15 |
older children | 14 |
renal involvement | 14 |
artery dilatation | 14 |
higher incidence | 14 |
hemorrhagic edema | 14 |
classifi cation | 14 |
ace expression | 14 |
system involvement | 14 |
dermatology outpatient | 14 |
supplementary table | 14 |
large vessel | 14 |
inflammatory response | 14 |
gastrointestinal symptoms | 14 |
heavy chain | 14 |
neonatal purpura | 14 |
hearing loss | 14 |
environmental factors | 14 |
fase aguda | 14 |
fl ammation | 14 |
small vessel | 14 |
fl ammatory | 14 |
anterior uveitis | 14 |
systemic lupus | 14 |
may result | 14 |
significant differences | 14 |
healthy children | 14 |
disease susceptibility | 14 |
complement activation | 14 |
mg day | 14 |
less severe | 14 |
gastrointestinal tract | 14 |
los casos | 14 |
acute hemorrhagic | 13 |
tei index | 13 |
erythema gyratum | 13 |
speci fi | 13 |
tract infection | 13 |
increased incidence | 13 |
cardiac involvement | 13 |
disease onset | 13 |
side effects | 13 |
mononuclear cells | 13 |
physical examination | 13 |
remains unknown | 13 |
laboratory tests | 13 |
polymyalgia rheumatica | 13 |
bacillus calmette | 13 |
lung injury | 13 |
effi cacy | 13 |
randomized trial | 13 |
aneurysm formation | 13 |
identifi ed | 13 |
mouse model | 13 |
renal disease | 13 |
high risk | 13 |
patients may | 13 |
syndrome toxin | 12 |
pediatric population | 12 |
systematic review | 12 |
arterial wall | 12 |
blood count | 12 |
dose intravenous | 12 |
synthetic clusters | 12 |
high incidence | 12 |
may present | 12 |
dose asa | 12 |
affected patients | 12 |
autoimmune disease | 12 |
controlled trial | 12 |
shock protein | 12 |
clinical diagnosis | 12 |
literature review | 12 |
idiopathic arthritis | 12 |
specific antibodies | 12 |
disease activity | 12 |
mycoplasma pneumoniae | 12 |
mean age | 12 |
different countries | 12 |
rheumatoid factor | 12 |
susceptible children | 12 |
hla class | 12 |
aseptic meningitis | 12 |
juvenile idiopathic | 12 |
ivig therapy | 12 |
influenza virus | 12 |
severely affected | 12 |
infantile acute | 12 |
severe kawasaki | 12 |
hyperinflammatory shock | 12 |
laboratory data | 12 |
cutaneous manifestations | 12 |
rheumatoid arthritis | 12 |
gene expression | 12 |
association studies | 12 |
signaling pathway | 11 |
immunoglobulin heavy | 11 |
fl iximab | 11 |
old girl | 11 |
lesions may | 11 |
least days | 11 |
important role | 11 |
cases per | 11 |
san diego | 11 |
study identifies | 11 |
cytoplasmic antibody | 11 |
blood vessel | 11 |
pediatric intensive | 11 |
scientific statement | 11 |
coronary abnormalities | 11 |
children presenting | 11 |
neutrophil cytoplasmic | 11 |
alanine aminotransferase | 11 |
pulse therapy | 11 |
fi cant | 11 |
defi ned | 11 |
high dose | 11 |
pericardial effusion | 11 |
genetic studies | 11 |
myocardial injury | 11 |
less common | 11 |
autosomal dominant | 11 |
animal model | 11 |
control group | 11 |
human herpesvirus | 11 |
giant aneurysms | 11 |
sterile pyuria | 11 |
immune dysregulation | 11 |
se ha | 11 |
fi ed | 11 |
healthy controls | 11 |
identi fi | 11 |
cardiac complications | 11 |
one case | 11 |
puede ser | 11 |
magnetic resonance | 11 |
genetic factors | 11 |
bilateral conjunctival | 11 |
term consequences | 11 |
measles infection | 11 |
neonatal period | 11 |
mononeuritis multiplex | 11 |
biopsy specimens | 11 |
american college | 11 |
taiwanese children | 11 |
artery involvement | 11 |
shock proteins | 11 |
disease among | 11 |
ethnic groups | 11 |
inclusion bodies | 10 |
severe cases | 10 |
lactobacillus casei | 10 |
serum sickness | 10 |
gut microbiome | 10 |
written informed | 10 |
elevated levels | 10 |
signifi cant | 10 |
diagnostic test | 10 |
observational cohort | 10 |
term follow | 10 |
blood cells | 10 |
single dose | 10 |
clinical spectrum | 10 |
three patients | 10 |
plasma exchange | 10 |
artery complications | 10 |
ammatory disease | 10 |
kd susceptibility | 10 |
many cases | 10 |
acetylsalicylic acid | 10 |
febrile neutrophilic | 10 |
cell count | 10 |
adenovirus infection | 10 |
study group | 10 |
fi cation | 10 |
atypical kd | 10 |
east asian | 10 |
control children | 10 |
helper cells | 10 |
treatment response | 10 |
less frequently | 10 |
bronchial epithelium | 10 |
coronary aneurysm | 10 |
ivig administration | 10 |
data suggest | 10 |
glucocorticoid therapy | 10 |
north america | 10 |
necrotizing vasculitis | 10 |
bcg inoculation | 10 |
disease process | 10 |
en un | 10 |
highest incidence | 10 |
cluster cases | 10 |
insuffi ciency | 10 |
microscopic polyangiitis | 10 |
evidence suggests | 10 |
neutrophilic dermatosis | 10 |
thoracic imaging | 10 |
aha guidelines | 10 |
direct immunofl | 10 |
may require | 10 |
case reports | 10 |
blueberry muffi | 10 |
leading cause | 10 |
fl ow | 10 |
pediatric inflammatory | 10 |
clinical signs | 10 |
hemophagocytic lymphohistiocytosis | 10 |
clinical practice | 10 |
pro bnp | 10 |
intestinal microbiota | 10 |
intravenous immune | 10 |
bone marrow | 10 |
autoimmune diseases | 10 |
associated vasculitides | 10 |
previous studies | 10 |
patients presenting | 10 |
disease fl | 9 |
retrospective study | 9 |
cal formation | 9 |
retropharyngeal abscess | 9 |
amino acid | 9 |
lymphoid involvement | 9 |
bacterial infections | 9 |
infections associated | 9 |
platelet counts | 9 |
epidemiologic features | 9 |
fever lasting | 9 |
high aso | 9 |
endothelial growth | 9 |
protein levels | 9 |
intravenous gammaglobulin | 9 |
leukocytoclastic vasculitis | 9 |
etiologic agents | 9 |
also occur | 9 |
ejection fraction | 9 |
pediatric mis | 9 |
nasopharyngeal swab | 9 |
protein homeostasis | 9 |
characteristic clinical | 9 |
respiratory syncytial | 9 |
nitric oxide | 9 |
clinical data | 9 |
sized arteries | 9 |
coronary angiography | 9 |
human gut | 9 |
like symptoms | 9 |
liver function | 9 |
adult covid | 9 |
mucocutaneous syndrome | 9 |
chlamydia pneumoniae | 9 |
successfully treated | 9 |
vascular endothelium | 9 |
japan kawasaki | 9 |
develop coronary | 9 |
kd remains | 9 |
respiratory disease | 9 |
new infantile | 9 |
organ involvement | 9 |
infl iximab | 9 |
monoclonal antibody | 9 |
critically ill | 9 |
signifi cantly | 9 |
proinflammatory cytokines | 9 |
children years | 9 |
venous thrombosis | 9 |
health information | 9 |
genetic susceptibility | 9 |
familial cold | 9 |
multiple organs | 9 |
neonatal onset | 9 |
convalescent phase | 9 |
ocular manifestations | 9 |
patients will | 9 |
clinical findings | 9 |
viral isolation | 9 |
disease severity | 9 |
corticosteroid therapy | 9 |
high levels | 9 |
first days | 9 |
arterial lesions | 9 |
conventional antigen | 9 |
old boy | 9 |
necrotizing glomerulonephritis | 9 |
antibiotic therapy | 9 |
murine model | 9 |
extremity changes | 9 |
immune suppression | 9 |
asian countries | 9 |
right coronary | 9 |
cold urticaria | 9 |
italian epicentre | 9 |
suffi cient | 9 |
acute systemic | 9 |
immune reaction | 9 |
genetic association | 9 |
inflammatory state | 8 |
mucous membranes | 8 |
dermal erythropoiesis | 8 |
acute rheumatic | 8 |
itpkc gene | 8 |
young adults | 8 |
aged years | 8 |
recent study | 8 |
clinical picture | 8 |
disease control | 8 |
innate immunity | 8 |
fl ares | 8 |
cardiac sequelae | 8 |
severe kd | 8 |
asian populations | 8 |
age group | 8 |
epidemiological studies | 8 |
nonsynonymous snvs | 8 |
respiratory infection | 8 |
disease detection | 8 |
hypersensitivity vasculitis | 8 |
individual lesions | 8 |
elastic lamina | 8 |
reverse transcriptase | 8 |
authors declare | 8 |
kd incidence | 8 |
also known | 8 |
neutrophil activation | 8 |
binding lectin | 8 |
vascular wall | 8 |
elevated inflammatory | 8 |
genetic polymorphisms | 8 |
injured cells | 8 |
acute lung | 8 |
crucial role | 8 |
fi brosis | 8 |
onset juvenile | 8 |
genetic predisposition | 8 |
long term | 8 |
epidemiological data | 8 |
disease long | 8 |
syncytial virus | 8 |
performed using | 8 |
nationwide survey | 8 |
superfi cial | 8 |
children younger | 8 |
recently reported | 8 |
vessel walls | 8 |
iga response | 8 |
maculopapular rash | 8 |
children aged | 8 |
polymorphism associated | 8 |
oral ulcers | 8 |
endothelial dysfunction | 8 |
transforming growth | 8 |
activated protein | 8 |
diagnostic challenge | 8 |
respiratory illness | 8 |
candida albicans | 8 |
visual loss | 8 |
artery dilation | 8 |
left coronary | 8 |
hsp nephritis | 8 |
second ivig | 8 |
pediatr doi | 8 |
manifestations include | 8 |
laboratory values | 8 |
cerebrospinal fl | 8 |
infants younger | 8 |
distress syndrome | 8 |
polymorphous exanthema | 8 |
weight loss | 8 |
treatment options | 8 |
subacute phase | 8 |
disease pathogenesis | 8 |
bcg scar | 8 |
intestinal microflora | 8 |
rapidly progressive | 8 |
pensar en | 8 |
mortality rate | 8 |
giant coronary | 8 |
single infusion | 8 |
year follow | 8 |
host defense | 8 |
multisystem infl | 8 |
oral mucosa | 8 |
syndrome associated | 8 |
early infancy | 8 |
defining characteristics | 8 |
median age | 8 |
single nucleotide | 8 |
pediatric cases | 8 |
bcg vaccination | 8 |
previously healthy | 8 |
paediatric inflammatory | 8 |
classic kd | 8 |
type iii | 8 |
acute heart | 8 |
fase subaguda | 8 |
grade fever | 8 |
globulin treatment | 7 |
supervised data | 7 |
itpkc functional | 7 |
least one | 7 |
classi fi | 7 |
red blood | 7 |
ighv genes | 7 |
liver failure | 7 |
disease date | 7 |
gm kg | 7 |
cardiac function | 7 |
classical kawasaki | 7 |
may develop | 7 |
systemic onset | 7 |
aso group | 7 |
early stage | 7 |
young infants | 7 |
cardiac dysfunction | 7 |
complete blood | 7 |
systemic circulation | 7 |
association analysis | 7 |
patients without | 7 |
resistant kd | 7 |
group compared | 7 |
iga plasma | 7 |
lower respiratory | 7 |
inflammasome activation | 7 |
chest pain | 7 |
control study | 7 |
viral pcr | 7 |
genetic variants | 7 |
immunosuppressive agents | 7 |
care unit | 7 |
without concurrent | 7 |
system inflammatory | 7 |
may help | 7 |
hyperinflammatory state | 7 |
dysregulated immune | 7 |
bilateral non | 7 |
adaptive immunity | 7 |
i cryoglobulinemia | 7 |
artery outcome | 7 |
infectious etiology | 7 |
toxic epidermal | 7 |
review board | 7 |
blood mononuclear | 7 |
specifi city | 7 |
disease genetics | 7 |
without respiratory | 7 |
japanese patients | 7 |
disease coronary | 7 |
type lectin | 7 |
acute pediatric | 7 |
home birth | 7 |
table shows | 7 |
cytoplasmic autoantibodies | 7 |
periungual desquamation | 7 |
institutional review | 7 |
studies suggest | 7 |
true cluster | 7 |
histopathologic examination | 7 |
ocular disease | 7 |
cutaneous lesions | 7 |
human herpes | 7 |
raise study | 7 |
maintenance therapy | 7 |
cell surface | 7 |
cell injury | 7 |
molecular mimicry | 7 |
tomisaku kawasaki | 7 |
maternal antibodies | 7 |
genetic determinants | 7 |
annual incidence | 7 |
smooth muscle | 7 |
phase i | 7 |
functional polymorphism | 7 |
hypocomplementemic urticarial | 7 |
cardiovascular complications | 7 |
secreting staphylococcus | 7 |
within days | 7 |
benefi cial | 7 |
infectious trigger | 7 |
serine protease | 7 |
different ethnic | 7 |
cytokine release | 7 |
also reported | 7 |
normal aso | 7 |
disease prevalence | 7 |
cardiogenic shock | 7 |
autoinflammatory diseases | 7 |
patients treated | 7 |
incomplete clinical | 7 |
active disease | 7 |
detection rate | 7 |
several years | 7 |
liver enzymes | 7 |
gas infections | 7 |
nationwide surveys | 7 |
control clusters | 7 |
epidemiologic study | 7 |
critically reviewed | 7 |
cell responses | 7 |
artery inflammation | 7 |
todos los | 7 |
even though | 7 |
previously described | 7 |
fi brinoid | 7 |
retrospective review | 7 |
cell clones | 7 |
johnson syndrome | 7 |
temporal clustering | 7 |
epidermal necrolysis | 7 |
infi ltration | 7 |
ii molecules | 7 |
large number | 7 |
significantly lower | 7 |
nk cells | 7 |
left anterior | 7 |
kawasaki es | 7 |
first presentation | 7 |
low incidence | 7 |
ca complication | 7 |
disease complicated | 7 |
typical pediatric | 7 |
acute intermittent | 7 |
sensorineural hearing | 7 |
los criterios | 7 |
confirmed measles | 7 |
polymorphous rash | 7 |
computed tomography | 7 |
muscular arteries | 7 |
anterior descending | 7 |
multinucleated giant | 7 |
predominantly affects | 7 |
confi rmed | 7 |
first ivig | 7 |
intestinal mucosa | 7 |
intermittent porphyria | 7 |
may reflect | 7 |
bacterial cervical | 7 |
taiwanese population | 7 |
acute urticaria | 7 |
mimicking kawasaki | 7 |
temporal association | 7 |
subconjunctival hemorrhages | 7 |
mycophenolate mofetil | 7 |
data collection | 7 |
retinal vasculitis | 7 |
chronic infl | 7 |
chain repertoire | 7 |
fi ngers | 7 |
producing bacteria | 7 |
peak stage | 7 |
statistically significant | 6 |
disease manifestations | 6 |
laboratory evidence | 6 |
vascular tissue | 6 |
imaging study | 6 |
pulmonary nodules | 6 |
university hospital | 6 |
fecal samples | 6 |
inflammatory disease | 6 |
clinical trials | 6 |
higher rate | 6 |
blood fl | 6 |
cryoglobulinemic vasculitis | 6 |
approximately one | 6 |
gene polymorphism | 6 |
kd diagnosis | 6 |
confirmed cases | 6 |
respiratory infections | 6 |
epidemiology telling | 6 |
nucleotide polymorphisms | 6 |
disease genetic | 6 |
see table | 6 |
increased susceptibility | 6 |
middle east | 6 |
rheumatic heart | 6 |
fever hours | 6 |
function tests | 6 |
viral entry | 6 |
bowel disease | 6 |
los autores | 6 |
much less | 6 |
kd include | 6 |
disease incidence | 6 |
widely distributed | 6 |
clinical setting | 6 |
syndrome hospitalizations | 6 |
nephrotic syndrome | 6 |
prompt treatment | 6 |
peripheral nerves | 6 |
pulmonary artery | 6 |
age range | 6 |
aortic aneurysm | 6 |
systemic disease | 6 |
periarteritis nodosa | 6 |
diagnosis includes | 6 |
three times | 6 |
additional studies | 6 |
higher positive | 6 |
usually unilateral | 6 |
confi rming | 6 |
clinical impact | 6 |
signal transduction | 6 |
herpes virus | 6 |
terminal pro | 6 |
genetic variation | 6 |
viral respiratory | 6 |
bacterial infection | 6 |
disease clinical | 6 |
like syndrome | 6 |
three gwas | 6 |
chronic infantile | 6 |
multiple organ | 6 |
human bocavirus | 6 |
viral disease | 6 |
primary angiitis | 6 |
pulmonary emboli | 6 |
lumen diameter | 6 |
epidemiologic survey | 6 |
lung disease | 6 |
ciliated bronchial | 6 |
sore throat | 6 |
antibiotic use | 6 |
cytokine responses | 6 |
interleukin receptor | 6 |
tropospheric winds | 6 |
japanese children | 6 |
immunodefi ciency | 6 |
sized vessels | 6 |
globulin therapy | 6 |
many children | 6 |
artery diameter | 6 |
epidemiological features | 6 |
infection may | 6 |
general population | 6 |
nucleotide polymorphism | 6 |
type natriuretic | 6 |
wbc count | 6 |
oxide synthase | 6 |
fold increase | 6 |
cell receptors | 6 |
disease polymorphism | 6 |
pandemic period | 6 |
without infection | 6 |
limited vasculitis | 6 |
se presenta | 6 |
hyperinflammatory syndrome | 6 |
immunosuppressive therapy | 6 |
acute infectious | 6 |
myocardial dysfunction | 6 |
ii cryoglobulinemia | 6 |
se debe | 6 |
brinoid necrosis | 6 |
infectious triggers | 6 |
initial intravenous | 6 |
infantile neurological | 6 |
female ratio | 6 |
novel virus | 6 |
confi rm | 6 |
commensal bacteria | 6 |
system disease | 6 |
snp rs | 6 |
herpes simplex | 6 |
fever onset | 6 |
reactive oxygen | 6 |
coronavirus nl | 6 |
children kawasaki | 6 |
complete kd | 6 |
childhood vasculitis | 6 |
four patients | 6 |
casei cell | 6 |
skin rashes | 6 |
familial mediterranean | 6 |
significant difference | 6 |
hemolytic anemia | 6 |
several studies | 6 |
patients compared | 6 |
less likely | 6 |
diagnostic tool | 6 |
i iia | 6 |
erythematosus neonatal | 6 |
additional therapies | 6 |
patients diagnosed | 6 |
italian society | 6 |
clinical fi | 6 |
ear disease | 6 |
telling us | 6 |
blood tests | 6 |
liver transplantation | 6 |
disease development | 6 |
cytoplasmic inclusion | 6 |
throat swab | 6 |
class i | 6 |
left ventricular | 6 |
genetic variations | 6 |
etiological agent | 6 |
controlled study | 6 |
united kingdom | 6 |
gwas data | 6 |
hypersensitivity reactions | 6 |
adult patients | 6 |
least four | 6 |
antiviral therapy | 6 |
artery biopsy | 6 |
possible role | 6 |
findings suggest | 6 |
epithelial cells | 6 |
clinical presentations | 6 |
underlying cause | 6 |
future research | 6 |
kda ro | 6 |
candidate genes | 6 |
synthetic antibody | 6 |
hypersensitivity reaction | 6 |
typical acute | 6 |
shuffled clusters | 6 |
spike protein | 6 |
sole erythema | 6 |
small intestine | 6 |
concurrent respiratory | 6 |
viral etiology | 6 |
early infection | 6 |
scoring systems | 6 |
onset multisystem | 6 |
disease diagnosis | 6 |
european countries | 6 |
cardiac disease | 6 |
ethics committee | 6 |
mediated disease | 6 |
disease course | 6 |
pityriasis rosae | 6 |
may include | 6 |
commonly used | 6 |
one child | 6 |
mediterranean fever | 6 |
increased levels | 6 |
reported cases | 6 |
febrile patients | 6 |
predisposing factors | 6 |
japanese population | 6 |
congestive heart | 6 |
although kd | 6 |
anakinra mg | 6 |
linkage disequilibrium | 6 |
contact history | 6 |
hepatoerythropoietic porphyria | 6 |
large arteries | 6 |
lesiones coronarias | 6 |
south korea | 6 |
proteins including | 6 |
allele frequency | 6 |
sun exposure | 6 |
kd shock | 6 |
high fever | 6 |
treatment failure | 6 |
times higher | 6 |
los enfermos | 6 |
york city | 6 |
selective expansion | 6 |
antibody responses | 6 |
external elastic | 6 |
york state | 6 |
el exantema | 6 |
ammatory syndrome | 6 |
unexplained fever | 6 |
virus infections | 6 |
matrix metalloproteinase | 6 |
family members | 6 |
angiotensin converting | 6 |
monte carlo | 6 |
laboratory studies | 6 |
infected cells | 6 |
severe respiratory | 6 |
organ dysfunction | 6 |
vasa vasorum | 6 |
neurological cutaneous | 6 |
observational study | 6 |
rave trial | 6 |
tissue damage | 6 |
las formas | 6 |
coronary involvement | 6 |
patients showed | 6 |
early phase | 6 |
concomitant respiratory | 6 |
corticosteroid treatment | 6 |
en este | 6 |
may show | 6 |
cervical adenitis | 6 |
enfermedad es | 6 |
rheumatology criteria | 6 |
drug reactions | 6 |
significant associations | 6 |
one patient | 6 |
systolic function | 6 |
throat swabs | 5 |
disease high | 5 |
granulomatous infl | 5 |
vascular injury | 5 |
homeostasis system | 5 |
transmission electron | 5 |
positive rate | 5 |
pyrogenic exotoxin | 5 |
renal impairment | 5 |
cracked lips | 5 |
national institutes | 5 |
ocular infl | 5 |
disease itpkc | 5 |
mechanical ventilation | 5 |
clinical phenotype | 5 |
mediated vasculitis | 5 |
aspirin alone | 5 |
pediatric illnesses | 5 |
hypersensitivity syndrome | 5 |
less commonly | 5 |
adjacent segment | 5 |
cell wall | 5 |
thromboembolic complications | 5 |
seasonal variations | 5 |
reports suggest | 5 |
much higher | 5 |
gene snp | 5 |
leukocyte antigen | 5 |
resonance imaging | 5 |
virus pcr | 5 |
las arterias | 5 |
internal diameter | 5 |
good clinical | 5 |
steroid pulse | 5 |
major histocompatibility | 5 |
brain natriuretic | 5 |
profi le | 5 |
acute streptococcal | 5 |
may even | 5 |
strongly associated | 5 |
gastrointestinal involvement | 5 |
adverse events | 5 |
sized muscular | 5 |
heart diseases | 5 |
clinical improvement | 5 |
expression levels | 5 |
natural history | 5 |
may trigger | 5 |
without coronary | 5 |
inflammatory cytokine | 5 |
positive patients | 5 |
stage renal | 5 |
also present | 5 |
myocardial velocity | 5 |
two patients | 5 |
presenta en | 5 |
many studies | 5 |
confl uent | 5 |
ocular complications | 5 |
fl uorescence | 5 |
en dosis | 5 |
disease lack | 5 |
ndings include | 5 |
age distribution | 5 |
prevent coronary | 5 |
novel case | 5 |
inciting agent | 5 |
disease relapses | 5 |
promoter polymorphism | 5 |
circulating endothelial | 5 |
different clinical | 5 |
gyratum atrophicans | 5 |
term outcome | 5 |
mucous membrane | 5 |
standard treatment | 5 |
small subset | 5 |
associated renal | 5 |
developed coronary | 5 |
en una | 5 |
subglottic stenosis | 5 |
nasopharyngeal swabs | 5 |
cutanea tarda | 5 |
african americans | 5 |
term treatment | 5 |
jaw claudication | 5 |
bcg vaccine | 5 |
also showed | 5 |
type diabetes | 5 |
various viruses | 5 |
genetics consortium | 5 |
giant aneurysm | 5 |
diagnostic guidelines | 5 |
pulmonary capillaritis | 5 |
complete congenital | 5 |
el sst | 5 |
igm antibodies | 5 |
severe illness | 5 |
vascular insuffi | 5 |
related morbidity | 5 |
developing coronary | 5 |
plasma cell | 5 |
including kd | 5 |
intravenous infusion | 5 |
salicylate dose | 5 |
ammatory infi | 5 |
current treatment | 5 |
univariate analysis | 5 |
los aneurismas | 5 |
tissue cells | 5 |
korean children | 5 |
three new | 5 |
en ocasiones | 5 |
one third | 5 |
common pathway | 5 |
wind patterns | 5 |
logistic regression | 5 |
anca titers | 5 |
organ system | 5 |
streptococcus spp | 5 |
membrane oxygenation | 5 |
tract infections | 5 |
premature infant | 5 |
complex deposition | 5 |
uorescence studies | 5 |
similar clinical | 5 |
year period | 5 |
east asia | 5 |
standard therapy | 5 |
coronary lesions | 5 |
gold standard | 5 |
ivig responders | 5 |
crescentic glomerulonephritis | 5 |
kawasaki shock | 5 |
small intestinal | 5 |
nationwide epidemiologic | 5 |
antibodies may | 5 |
bilateral nonexudative | 5 |
gall bladder | 5 |
temporal clusters | 5 |
initial manuscript | 5 |
remission maintenance | 5 |
protective role | 5 |
bilateral subconjunctival | 5 |
es muy | 5 |
maternal antibody | 5 |
steroid therapy | 5 |
comparative study | 5 |
amino acids | 5 |
intestinal tract | 5 |
susceptible individuals | 5 |
sixth day | 5 |
specific desquamation | 5 |
dose ivig | 5 |
incomplete form | 5 |
disease toxic | 5 |
two groups | 5 |
emerging reports | 5 |
dendritic cells | 5 |
streptococcal pyrogenic | 5 |
vasculitis associated | 5 |
por el | 5 |
neutralizing abs | 5 |
cervical adenopathy | 5 |
microbiologic testing | 5 |
ischemic complications | 5 |
cytokine imbalance | 5 |
total protein | 5 |
usually self | 5 |
receptor gene | 5 |
iii synthase | 5 |
etanercept trial | 5 |
higher rates | 5 |
iv methylprednisolone | 5 |
infectious origin | 5 |
disease within | 5 |
extracorporeal membrane | 5 |
positive rates | 5 |
systemic vasculitides | 5 |
laboratory abnormalities | 5 |
frecuente en | 5 |
causative agent | 5 |
crp levels | 5 |
arterias coronarias | 5 |
elevated aso | 5 |
anca patients | 5 |
intimal hyperplasia | 5 |
autoinfl ammatory | 5 |
evidence support | 5 |
within blood | 5 |
variegate porphyria | 5 |
disease key | 5 |
cd cells | 5 |
may play | 5 |
early stages | 5 |
conventional angiography | 5 |
disease prediction | 5 |
chronic urticaria | 5 |
dose glucocorticoids | 5 |
liver disease | 5 |
financial relationships | 5 |
purpura nephritis | 5 |
peripheral extremities | 5 |
pcr test | 5 |
target cells | 5 |
total number | 5 |
early detection | 5 |
vessel involvement | 5 |
vasculitis affecting | 5 |
normal range | 5 |
without sequelae | 5 |
con el | 5 |
infection kawasaki | 5 |
high titers | 5 |
clinical sign | 5 |
demographic characteristics | 5 |
infections may | 5 |
propionibacterium acnes | 5 |
plus prednisolone | 5 |
human leukocyte | 5 |
septic shock | 5 |
por su | 5 |
genetically predisposed | 5 |
enzyme gene | 5 |
previous reports | 5 |
specifi cally | 5 |
infection associated | 5 |
disease intravenous | 5 |
may cause | 5 |
major role | 5 |
early life | 5 |
mefv mutations | 5 |
nlrp inflammasome | 5 |
coronary damage | 5 |
dermoepidermal junction | 5 |
cardiovascular involvement | 5 |
antibody response | 5 |
con una | 5 |
inner ear | 5 |
intravenous cyclophosphamide | 5 |
metagenomic analysis | 5 |
complementary pr | 5 |
clinical feature | 5 |
porphyria cutanea | 5 |
received ivig | 5 |
highly dependent | 5 |
pediatric rheumatology | 5 |
gyratum perstans | 5 |
receptor variable | 5 |
fever persisting | 5 |
agents may | 5 |
guide treatment | 5 |
conventional antigens | 5 |
syndrome may | 5 |
clinical manifestation | 5 |
recent studies | 5 |
erythema elevatum | 5 |
parainfluenza type | 5 |
western countries | 5 |
aortic endothelial | 5 |
granulomatosis etanercept | 5 |
respiratory virus | 5 |
tropospheric wind | 5 |
genetic risk | 5 |
kd pathogenesis | 5 |
bulbar conjunctivitis | 5 |
unknown etiology | 5 |
radiographic findings | 5 |
myeloid cells | 5 |
frequently observed | 5 |
per million | 5 |
within hours | 5 |
cutaneous vasculitis | 5 |
complete resolution | 5 |
chest radiographs | 5 |
organ systems | 5 |
fi cient | 5 |
fc gamma | 5 |
antigen presentation | 5 |
autosomal recessive | 5 |
factors associated | 5 |
elevatum diutinum | 5 |
variable regions | 5 |
laboratory parameters | 5 |
homozygous variegate | 5 |
significantly associated | 5 |
ischemic heart | 5 |
urinary tract | 5 |
oral mucosal | 5 |
atypical presentations | 5 |
apoptotic neutrophils | 5 |
secreting bacteria | 5 |
myocardial ischemia | 5 |
serum levels | 5 |
immunological response | 5 |
immune phenotypes | 5 |
younger children | 5 |
northeastern china | 5 |
formas incompletas | 5 |
also common | 5 |
disease characterized | 5 |
las lesiones | 5 |
therapeutic approaches | 5 |
first dose | 5 |
treatment may | 5 |
los primeros | 5 |
disease characterization | 5 |
susceptibility genes | 5 |
kd clusters | 5 |
connective tissue | 5 |
proper clinical | 5 |
public health | 5 |
entre los | 5 |
pilot study | 5 |
positive results | 5 |
clinical phenotypes | 5 |
physical urticarias | 5 |
untreated children | 5 |
immune reactions | 5 |
global sars | 5 |
left ventricle | 5 |
single intravenous | 5 |
profound lymphopenia | 5 |
systemic juvenile | 5 |
eosinophilic infi | 5 |
ng ml | 5 |
evidence based | 5 |
granuloma formation | 5 |
distinct clinical | 5 |
glucocorticoids alone | 5 |
limited disease | 5 |
immunoglobulin plus | 5 |
streptococcal toxic | 5 |
angiotensin ii | 5 |
marrow transplantation | 5 |
first described | 5 |
es con | 4 |
mortality due | 4 |
immunoglobulin unresponsiveness | 4 |
erythematous rash | 4 |
temporal arteries | 4 |
skin fragility | 4 |
mitral regurgitation | 4 |
cell function | 4 |
artery lesion | 4 |
admission data | 4 |
polymorphous skin | 4 |
develop caas | 4 |
methylprednisolone pulse | 4 |
states kawasaki | 4 |
adenovirus detection | 4 |
chain fatty | 4 |
fi nition | 4 |
hereditary coproporphyria | 4 |
evidence suggesting | 4 |
pan cases | 4 |
girl presented | 4 |
inner border | 4 |
natural killer | 4 |
agent may | 4 |
human adenovirus | 4 |
ca dilatation | 4 |
highly specific | 4 |
skin syndrome | 4 |
commonly implicated | 4 |
certain clinical | 4 |
cation criteria | 4 |
studies will | 4 |
distal segments | 4 |
test results | 4 |
distributed infectious | 4 |
intracytoplasmic inclusion | 4 |
patients presented | 4 |
lymphocyte ratio | 4 |
although patients | 4 |
ef fi | 4 |
clinical expression | 4 |
ssa ro | 4 |
classifi ed | 4 |
han chinese | 4 |
related susceptibility | 4 |
scalded skin | 4 |
also develop | 4 |
observations suggest | 4 |
hospitalized children | 4 |
increasingly used | 4 |
nfat signaling | 4 |
certain genetic | 4 |
medical center | 4 |
hospital birth | 4 |
disease update | 4 |
world health | 4 |
key role | 4 |
received antibiotics | 4 |
may differ | 4 |
deep venous | 4 |
acute inflammatory | 4 |
pulmonary disease | 4 |
echocardiography showed | 4 |
clinical experience | 4 |
early coronary | 4 |
troponin i | 4 |
pleural effusions | 4 |
ill children | 4 |
renal failure | 4 |
several weeks | 4 |
alrededor del | 4 |
disease identification | 4 |
etiological agents | 4 |
microbial community | 4 |
least two | 4 |
bilateral conjunctivitis | 4 |
older age | 4 |
serologic testing | 4 |
strongly suggest | 4 |
myocardial depression | 4 |
specific diagnostic | 4 |
rare instances | 4 |
con gammaglobulina | 4 |
resonance angiography | 4 |
lengua aframbuesada | 4 |
mefv mutation | 4 |
weight heparin | 4 |
casp confer | 4 |
kidney injury | 4 |
data regarding | 4 |
individual patients | 4 |
specific immune | 4 |
may aid | 4 |
blood type | 4 |
seasonal variation | 4 |
fatty acids | 4 |
artery damage | 4 |
previously known | 4 |
hong kong | 4 |
almost always | 4 |
meningococcal disease | 4 |
incidence survey | 4 |
enzymatic activity | 4 |
often diagnosed | 4 |
human immunodeficiency | 4 |
similar results | 4 |
based approach | 4 |
like receptors | 4 |
pediatric multi | 4 |
adhesion molecule | 4 |
main cause | 4 |
fl uence | 4 |
es un | 4 |
disease selective | 4 |
per year | 4 |
recessive inheritance | 4 |
clinical syndrome | 4 |
del shock | 4 |
laboratory criteria | 4 |
aspirin plus | 4 |
occurs predominantly | 4 |
gammaglobulin treatment | 4 |
antibodies directed | 4 |
clinical studies | 4 |
one month | 4 |
limited wg | 4 |
immune cell | 4 |
primary treatment | 4 |
positive viral | 4 |
recovered patients | 4 |
left circumflex | 4 |
relatively common | 4 |
oligoclonal iga | 4 |
common pediatric | 4 |
cases within | 4 |
associated systemic | 4 |
larger number | 4 |
elevated esr | 4 |
factor alpha | 4 |
bcg site | 4 |
synthase gene | 4 |
phase iii | 4 |
mycobacterium bovis | 4 |
iximab treatment | 4 |
patients admitted | 4 |
online health | 4 |
anecdotal reports | 4 |
iii cryoglobulinemia | 4 |
febrile illness | 4 |
genes associated | 4 |
remains unclear | 4 |
extracellular traps | 4 |
progressive glomerulonephritis | 4 |
elevated il | 4 |
oral charcoal | 4 |
infi ltrative | 4 |
nationwide epidemiological | 4 |
oxygen species | 4 |
cell immunity | 4 |
neutrophil extracellular | 4 |
defi ciencies | 4 |
epsteinebarr virus | 4 |
infected patients | 4 |
horse serum | 4 |
immune defense | 4 |
vasculopathic processes | 4 |
viral load | 4 |
disease infliximab | 4 |
two entities | 4 |
diego county | 4 |
modi fi | 4 |
functional consequences | 4 |
patients show | 4 |
serologic tests | 4 |
disseminated intravascular | 4 |
new risk | 4 |
typical covid | 4 |
endothelial injury | 4 |
asa therapy | 4 |
factors may | 4 |
arterial aneurysms | 4 |
northern european | 4 |
important intellectual | 4 |
histocompatibility complex | 4 |
susceptible host | 4 |
aneurysmal dilatation | 4 |
disease results | 4 |
old infant | 4 |
normal flora | 4 |
resolve spontaneously | 4 |
positive test | 4 |
si hay | 4 |
often associated | 4 |
criterios mayores | 4 |
typical fever | 4 |
fulminant myocarditis | 4 |
extremely rare | 4 |
infliximab treatment | 4 |
two doses | 4 |
latin america | 4 |
robust immune | 4 |
clinical predictors | 4 |
potential conflict | 4 |
may need | 4 |
disease might | 4 |
el momento | 4 |
arteries may | 4 |
immunized mice | 4 |
systemic corticosteroids | 4 |
autoimmune responses | 4 |
five factor | 4 |
animal models | 4 |
american academy | 4 |
cutaneous symptoms | 4 |
health organization | 4 |
bene fi | 4 |
without treatment | 4 |
china carry | 4 |
geographical clustering | 4 |
recurrent disease | 4 |
cias gene | 4 |
antibiotic treatment | 4 |
ammatory disorder | 4 |
fi rm | 4 |
thrombocytopenic purpura | 4 |
young age | 4 |
retropharyngeal edema | 4 |
like coronary | 4 |
million confirmed | 4 |
es propio | 4 |
usually appears | 4 |
inflammatory mediators | 4 |
purpuric lesions | 4 |
monocytes macrophages | 4 |
viral exanthem | 4 |
leukocyte count | 4 |
ammatory process | 4 |
renal function | 4 |
scientific evidence | 4 |
will develop | 4 |
peripheral neuropathy | 4 |
inflammatory processes | 4 |
en su | 4 |
ivig alone | 4 |
cytotoxic agents | 4 |
epidemiologic characteristics | 4 |
kd without | 4 |
cardiovascular sequelae | 4 |
tissue ischemia | 4 |
relatively uncommon | 4 |
febrile illnesses | 4 |
medical centre | 4 |
cerebral venous | 4 |
two diseases | 4 |
common variants | 4 |
remain unclear | 4 |
kd includes | 4 |
may contribute | 4 |
culture supernatants | 4 |
drug eruption | 4 |
typical kd | 4 |
receptor binding | 4 |
cutaneous neonatal | 4 |
disease iga | 4 |
erythema nodosum | 4 |
antineutrophil cytoplasm | 4 |
immunoglobulin therapy | 4 |
affecting children | 4 |
drug reaction | 4 |
ha descrito | 4 |
time course | 4 |
patients also | 4 |
five years | 4 |
vast majority | 4 |
serial echocardiograms | 4 |
higher prevalence | 4 |
kd might | 4 |
lectin genotype | 4 |
ventricular function | 4 |
bacille calmette | 4 |
lower platelet | 4 |
incidence rate | 4 |
el enfermo | 4 |
east respiratory | 4 |
usually present | 4 |
performed statistical | 4 |
epidemiological characteristics | 4 |
cardiac mri | 4 |
reticuloendothelial system | 4 |
enzyme immunoassays | 4 |
hospital admission | 4 |
reye syndrome | 4 |
cov infection | 4 |
neutralizing antibodies | 4 |
six months | 4 |
skin involvement | 4 |
insertion deletion | 4 |
nose deformity | 4 |
artery abnormality | 4 |
multiple cohorts | 4 |
resolve completely | 4 |
palpable purpura | 4 |
mononuclear infi | 4 |
four infusions | 4 |
el tratamiento | 4 |
serious adverse | 4 |
examination revealed | 4 |
transiens neonatale | 4 |
gov nct | 4 |
inflammatory effect | 4 |
severe inflammatory | 4 |
renal vasculitis | 4 |
el enrojecimiento | 4 |
th cells | 4 |
acute kidney | 4 |
interleukin gene | 4 |
cardiovascular issues | 4 |
greater risk | 4 |
treatment decisions | 4 |
mildly symptomatic | 4 |
competing interests | 4 |
se puede | 4 |
rare presentation | 4 |
made based | 4 |
critical review | 4 |
otitis media | 4 |
common feature | 4 |
atrophicans transiens | 4 |
initial doses | 4 |
associated multisystem | 4 |
clinical deterioration | 4 |
otras enfermedades | 4 |
sars coronavirus | 4 |
patients recovered | 4 |
superantigenic activity | 4 |
lesions associated | 4 |
adhesion molecules | 4 |
renal insuffi | 4 |
immunodeficiency virus | 4 |
case definition | 4 |
statistical analyses | 4 |
human coronaviruses | 4 |
left main | 4 |
transient porphyrinemia | 4 |
risk loci | 4 |
corresponding immune | 4 |
kd suggests | 4 |
prominent role | 4 |
endpoints trial | 4 |
enfermos con | 4 |
northern italy | 4 |
globulin dose | 4 |
molecular techniques | 4 |
ubiquitous infectious | 4 |
anterior chamber | 4 |
hemolytic disease | 4 |
neonatal mortality | 4 |
common clinical | 4 |
molecular mechanisms | 4 |
novel susceptibility | 4 |
thrombotic complications | 4 |
enzyme immunoassay | 4 |
aneurysms may | 4 |
reports indicate | 4 |
articular syndrome | 4 |
confi rmation | 4 |
identifies three | 4 |
treatment regimen | 4 |
una media | 4 |
intravenous immunoglobulins | 4 |
clinical outcome | 4 |
viral loads | 4 |
cdr clonotypes | 4 |
anemia may | 4 |
low doses | 4 |
stage iii | 4 |
usually associated | 4 |
clinical diagnostic | 4 |
coronary outcome | 4 |
crust formation | 4 |
es una | 4 |
geographic clustering | 4 |
enrolled children | 4 |
myocardial function | 4 |
adult cardiovascular | 4 |
seven patients | 4 |
cardiovascular abnormalities | 4 |
confi ned | 4 |
new virus | 4 |
stage analysis | 4 |
staphylococcal scalded | 4 |
mpo antibodies | 4 |
human disease | 4 |
recurrence rate | 4 |
influenza viruses | 4 |
signaling pathways | 4 |
disease increased | 4 |
clinical conditions | 4 |
another study | 4 |
enfermedad se | 4 |
based study | 4 |
disease occurs | 4 |
often misdiagnosed | 4 |
high doses | 4 |
endothelial damage | 4 |
therapeutic options | 4 |
cell infi | 4 |
avian influenza | 4 |
two types | 4 |
facial nerve | 4 |
blood pressure | 4 |
acute disease | 4 |
immune mechanisms | 4 |
positive cocci | 4 |
bulbar conjunctival | 4 |
study design | 4 |
lower incidence | 4 |
circulating immune | 4 |
identifi cation | 4 |
dengue virus | 4 |
matrix metalloproteinases | 4 |
early diagnosis | 4 |
multicenter trial | 4 |
pulmonary embolism | 4 |
amniotic fl | 4 |
peripheral facial | 4 |
disease caused | 4 |
using culture | 4 |
pathologic lesions | 4 |
tyrosine kinase | 4 |
acute myocarditis | 4 |
data supporting | 4 |
infl amed | 4 |
also found | 4 |
protective effect | 4 |
pathogen recognition | 4 |
ro antibodies | 4 |
secondary infections | 4 |
lactate dehydrogenase | 4 |
cesarean delivery | 4 |
descending artery | 4 |
functionally related | 4 |
albicans water | 4 |
key words | 4 |
current covid | 4 |
uroporphyrinogen iii | 4 |
severe sars | 4 |
mononuclear cell | 4 |
iga nephropathy | 4 |
rising incidence | 4 |
ighv region | 4 |
laboratory testing | 4 |
intellectual content | 4 |
typical clinical | 4 |
confer susceptibility | 4 |
study groups | 4 |
pmr patients | 4 |
nasal gene | 4 |
care units | 4 |
laboratory investigations | 4 |
hemophagocytic syndrome | 4 |
month old | 4 |
pulse methylprednisolone | 4 |
predominantly affecting | 4 |
host factors | 4 |
periungual peeling | 4 |
received anakinra | 4 |
intestinal flora | 4 |
initial infection | 4 |
peak age | 4 |
streptococcal superantigens | 4 |
disease research | 4 |
korean society | 4 |
esta enfermedad | 4 |
delayed development | 4 |
hyperimmune reaction | 4 |
molecular biology | 4 |
annular erythemas | 4 |
common viruses | 4 |
artery disease | 4 |
emla cream | 4 |
angiographic fi | 4 |
fi eld | 4 |
iu ml | 4 |
serologic evidence | 4 |
risk stratification | 4 |
initial therapy | 4 |
high prevalence | 4 |
immunosuppressive therapies | 4 |
mild elevation | 4 |
snvs within | 4 |
specific infectious | 4 |
abnormal immunological | 4 |
parainfluenza virus | 4 |
site erythema | 4 |
clinical evolution | 4 |
una enfermedad | 4 |
molecular level | 4 |
complex disease | 4 |
en esta | 4 |
part i | 4 |
clear guidelines | 4 |
wegener granulomatosis | 4 |
genetic associations | 4 |
oral cyclophosphamide | 4 |
elastin degradation | 4 |
adverse effects | 4 |
line therapy | 4 |
initial presentation | 4 |
simulation score | 4 |
primary hlh | 4 |
cambios en | 4 |
central role | 4 |
cinca syndrome | 4 |
th treg | 4 |
independent risk | 4 |
potential cardiovascular | 4 |
lupus syndrome | 4 |
heterogeneous infectious | 4 |
less often | 4 |
tissue doppler | 4 |
may become | 4 |
etiology remains | 4 |
inflammatory bowel | 4 |
exudative conjunctivitis | 4 |
deletion polymorphism | 4 |
peripheral gangrene | 4 |
following sars | 4 |
normal coronary | 4 |
significantly increased | 4 |
possibly due | 4 |
nerve palsy | 4 |
main clinical | 4 |
human kd | 4 |
kawasaki en | 4 |
three distinct | 4 |
ivig dose | 4 |
increased expression | 4 |
increased significantly | 4 |
genetic backgrounds | 4 |
glucocorticoid treatment | 4 |
scientific community | 4 |
mortality among | 4 |
ineffective treatments | 4 |
similar findings | 4 |
throat flora | 4 |
purulent cervical | 4 |
anca vasculitis | 4 |
brief history | 4 |
virus isolation | 4 |
vasculitis may | 4 |
cardiovascular pathology | 4 |
cholesterol levels | 4 |
final manuscript | 4 |
skin fi | 4 |
aneurismas coronarios | 4 |
kd affects | 4 |
multicenter study | 4 |
sample size | 4 |
diagnostic challenges | 4 |
many years | 4 |
pulmonary manifestations | 4 |
lymphoid tissue | 4 |
wells syndrome | 4 |
studies may | 4 |
main coronary | 4 |
cells expressing | 4 |
natural course | 4 |
resulted positive | 4 |
include erythema | 4 |
cd cd | 4 |
deposition within | 4 |
north india | 4 |
worldwide cases | 4 |
true data | 4 |
asian children | 4 |
cutaneous pan | 4 |
serological tests | 4 |
rosae patients | 4 |
time series | 4 |
divided doses | 4 |
prothrombotic coagulopathy | 4 |
vascular inflammation | 4 |
mild respiratory | 3 |
sa genes | 3 |
susceptibility locus | 3 |
type virus | 3 |
microscopic study | 3 |
phenotypes among | 3 |
data kawasaki | 3 |
eosinophilic gastroenteritis | 3 |
primary systemic | 3 |
environmental flora | 3 |
momento actual | 3 |
recurrent events | 3 |
bilateral peripheral | 3 |
single patient | 3 |
necrotizing fasciitis | 3 |
chemokine receptor | 3 |
febrile diseases | 3 |
infectious workup | 3 |
taken together | 3 |
elastin breakdown | 3 |
left untreated | 3 |
ks pathogenesis | 3 |
severe forms | 3 |
algunos autores | 3 |
term sequelae | 3 |
kg dose | 3 |
early treatment | 3 |
urticarial lesions | 3 |
dose anakinra | 3 |
like features | 3 |
springer nature | 3 |
storm syndrome | 3 |
el infarto | 3 |
porphyria congenital | 3 |
familial cases | 3 |
also characteristic | 3 |
primary infection | 3 |
tissue disease | 3 |
systematic literature | 3 |
proven infection | 3 |
slight dilatation | 3 |
wide array | 3 |
vasodilatory shock | 3 |
localized wg | 3 |
protective immunity | 3 |
nonspecific inflammatory | 3 |
increasing awareness | 3 |
hla antigens | 3 |
study kawasaki | 3 |
positive vasculitis | 3 |
coronary endothelial | 3 |
decreased levels | 3 |
fi gure | 3 |
sunexposed areas | 3 |
defi nitive | 3 |
es del | 3 |
receive ivig | 3 |
host response | 3 |
kd due | 3 |
may take | 3 |
new concept | 3 |
upper extremities | 3 |
recent advances | 3 |
algunas enfermedades | 3 |
tumour necrosis | 3 |
molecular weight | 3 |
acute self | 3 |
los reactantes | 3 |
virus associated | 3 |
increased permeability | 3 |
inherited thrombophilic | 3 |
similar hyperinflammatory | 3 |
receptor ace | 3 |
igm heavy | 3 |
note springer | 3 |
tissue injuries | 3 |
se produce | 3 |
anca production | 3 |
disease include | 3 |
lesions occur | 3 |
pulmonary haemorrhage | 3 |
highly specifi | 3 |
aortic arch | 3 |
test may | 3 |
eritema palmoplantar | 3 |
virtual case | 3 |
surgical treatment | 3 |
last decade | 3 |
severe lung | 3 |
developed world | 3 |
tertiary care | 3 |
activate neutrophils | 3 |
tissue edema | 3 |
reported patients | 3 |
postinfectious multisystem | 3 |
immune glomerulonephritis | 3 |
infection include | 3 |
vascular disease | 3 |
abdominal symptoms | 3 |
reported case | 3 |
time points | 3 |
normal systolic | 3 |
polymorphous exanthem | 3 |
inducible nitric | 3 |
including covid | 3 |
infectious cause | 3 |
new type | 3 |
anca pattern | 3 |
intestinal epithelial | 3 |
mediumsized arteries | 3 |
may therefore | 3 |
churg strauss | 3 |
i converting | 3 |
alpha levels | 3 |
involved organ | 3 |
one may | 3 |
disease recognition | 3 |
profi les | 3 |
currently ongoing | 3 |
nitive diagnosis | 3 |
igg heavy | 3 |
analysis reveals | 3 |
agents might | 3 |
gb virus | 3 |
low maternal | 3 |
regression analyses | 3 |
fl orid | 3 |
recientemente se | 3 |
medium vessel | 3 |
diseases may | 3 |
multicenter prospective | 3 |
suppression may | 3 |
airspace opacities | 3 |
nuestra experiencia | 3 |
disease mechanisms | 3 |
thrombotic microangiopathy | 3 |
genetic characteristics | 3 |
kd criteria | 3 |
ca nfat | 3 |
escherichia coli | 3 |
current recommendations | 3 |
following ivig | 3 |
infection due | 3 |
organ cultures | 3 |
cell antibodies | 3 |
virtual set | 3 |
kd treated | 3 |
cualquier exantema | 3 |
sequence reads | 3 |
cardiac features | 3 |
group versus | 3 |
mucosal changes | 3 |
drug hypersensitivity | 3 |
diastolic myocardial | 3 |
ligand pair | 3 |
common viral | 3 |
marshall syndrome | 3 |
lip changes | 3 |
acute infection | 3 |
classical criteria | 3 |
milk intolerance | 3 |
alveolar hemorrhage | 3 |
antiphospholipid syndrome | 3 |
higher ace | 3 |
syndrome erythema | 3 |
light microscopy | 3 |
pero con | 3 |
superantigen mediated | 3 |
foreign antigen | 3 |
three children | 3 |
con un | 3 |
fold higher | 3 |
possible atypical | 3 |
without evidence | 3 |
vital signs | 3 |
accurate diagnosis | 3 |
including enterovirus | 3 |
lesions consist | 3 |
affect children | 3 |
small proportion | 3 |
nk cell | 3 |
infarto agudo | 3 |
renal biopsies | 3 |
joint pain | 3 |
lower doses | 3 |
characterize kawasaki | 3 |
del comienzo | 3 |
first year | 3 |
subacute chronic | 3 |
induction therapy | 3 |
una vasculitis | 3 |
study clinical | 3 |
phase ii | 3 |
childhood vasculitides | 3 |
gca patients | 3 |
identifies fcgr | 3 |
frecuente es | 3 |
idiopathic pan | 3 |
en las | 3 |
patients infected | 3 |
angiotensin i | 3 |
hydroxyzine hydrochloride | 3 |
early summer | 3 |
neonatal jaundice | 3 |
streptococcal pharyngitis | 3 |
electron microscopy | 3 |
patients affected | 3 |
cell expansion | 3 |
various infectious | 3 |
almost exclusively | 3 |
kd associated | 3 |
like reactions | 3 |
incomplete penetrance | 3 |
delayed onset | 3 |
ko mice | 3 |
possible trigger | 3 |
studies published | 3 |
following covid | 3 |
significant clinical | 3 |
benign disease | 3 |
biopsy evidence | 3 |
se realiza | 3 |
complement system | 3 |
association criteria | 3 |
remains neutral | 3 |
human health | 3 |
limited clinical | 3 |
count mm | 3 |
children will | 3 |
cardiovascular collapse | 3 |
fl eeting | 3 |
complete recovery | 3 |
association kawasaki | 3 |
anticardiolipin antibodies | 3 |
acute infections | 3 |
pacific islanders | 3 |
low molecular | 3 |
limiting systemic | 3 |
genetic background | 3 |
potential association | 3 |
growing evidence | 3 |
term prognosis | 3 |
study suggests | 3 |
arterial dilatation | 3 |
often presents | 3 |
chang gung | 3 |
small vessels | 3 |
produce various | 3 |
possible kawasaki | 3 |
shlh mas | 3 |
incidental detection | 3 |
prompt clinical | 3 |
clinical use | 3 |
may often | 3 |
clinical finding | 3 |
elevated erythrocyte | 3 |
microbial agents | 3 |
fi brotic | 3 |
cytomegalovirus infection | 3 |
mediated diseases | 3 |
also suggests | 3 |
induced acute | 3 |
resident intestinal | 3 |
kd refractory | 3 |
bronchoalveolar lavage | 3 |
patient died | 3 |
resistant cases | 3 |
early intravenous | 3 |
es el | 3 |
si el | 3 |
within hrs | 3 |
various inflammatory | 3 |
los meses | 3 |
caucasian patients | 3 |
case highlights | 3 |
frequently reported | 3 |
venous system | 3 |
infi ltrating | 3 |
household members | 3 |
pulmonary phase | 3 |
vascular en | 3 |
mycobacterial heat | 3 |
author contributions | 3 |
kobayashi score | 3 |
recently published | 3 |
disease variant | 3 |
linkage analysis | 3 |
reverse transcription | 3 |
fold increased | 3 |
among persons | 3 |
may elicit | 3 |
significantly longer | 3 |
kyung hee | 3 |
harada score | 3 |
term cardiac | 3 |
aberrant immune | 3 |
nature remains | 3 |
rituximab versus | 3 |
gadolinium enhancement | 3 |
see chapter | 3 |
immunoglobulin molecules | 3 |
artritis es | 3 |
tubulointerstitial nephritis | 3 |
multiple agents | 3 |
intravenous methylprednisolone | 3 |
surgical drainage | 3 |
literature search | 3 |
vascular infl | 3 |
viruses including | 3 |
muscle cells | 3 |
first time | 3 |
ventricular systolic | 3 |
ursodeoxycholic acid | 3 |
disease concurrent | 3 |
proteins may | 3 |
complexes precipitate | 3 |
front pediatr | 3 |
may yield | 3 |
individual clusters | 3 |
inflammatory cascade | 3 |
recent observations | 3 |
infect dis | 3 |
whenever possible | 3 |
may represent | 3 |
common respiratory | 3 |
childhood infections | 3 |
clinical suspicion | 3 |
mpo loci | 3 |
urticaria may | 3 |
top snv | 3 |
abdominal ultrasound | 3 |
reference center | 3 |
important determinants | 3 |
fi cance | 3 |
postulated explanation | 3 |
tt virus | 3 |
exudative pharyngitis | 3 |
confounding bystander | 3 |
trimethoprim sulfamethoxazole | 3 |
may affect | 3 |
rst year | 3 |
multiracial male | 3 |
sudden death | 3 |
mast cell | 3 |
taiwan kawasaki | 3 |
socioeconomic status | 3 |
young diagnosis | 3 |
induce remission | 3 |
casos por | 3 |
ivig retreatment | 3 |
seems likely | 3 |
common fi | 3 |
processes characterize | 3 |
five days | 3 |
detect respiratory | 3 |
injection without | 3 |
bacterial toxin | 3 |
disease triggered | 3 |
rituxivas trial | 3 |
vascular lesions | 3 |
se manifiesta | 3 |
previous years | 3 |
european descent | 3 |
healthcare workers | 3 |
three major | 3 |
microcytic anemia | 3 |
considered statistically | 3 |
coronary disease | 3 |
relatively small | 3 |
two studies | 3 |
fl uorescein | 3 |
rna polymerase | 3 |
immunological features | 3 |
severe wg | 3 |
viral results | 3 |
mice infected | 3 |
low levels | 3 |
danger model | 3 |
pediatric cardiologist | 3 |
exaggerated inflammatory | 3 |
three linked | 3 |
acute viral | 3 |
major concern | 3 |
disease hla | 3 |
cell deficiency | 3 |
coronary anomalies | 3 |
may produce | 3 |
severe pneumonia | 3 |
cov infections | 3 |
rara en | 3 |
except one | 3 |
main results | 3 |
various factors | 3 |
aunque el | 3 |
six weeks | 3 |
serum igm | 3 |
cdc covid | 3 |
severe outcome | 3 |
multiforme major | 3 |
may account | 3 |
mild symptoms | 3 |
disease prevention | 3 |
proinflammatory response | 3 |
commonest cause | 3 |
coronavirus associated | 3 |
pathological study | 3 |
partial thromboplastin | 3 |
measles vaccination | 3 |
hee university | 3 |
odds ratio | 3 |
longterm management | 3 |
multiple myeloma | 3 |
el nombre | 3 |
para el | 3 |
familial aquagenic | 3 |
tract involvement | 3 |
standard deviation | 3 |
pediatric gastroenterologist | 3 |
power field | 3 |
kd occurs | 3 |
human monoclonal | 3 |
anca positive | 3 |
disease human | 3 |
factors influencing | 3 |
cause photosensitivity | 3 |
severe henoch | 3 |
early onset | 3 |
chest radiograph | 3 |
gyratum repens | 3 |
might contribute | 3 |
vasculitis syndrome | 3 |
erythrocyte protoporphyrins | 3 |
role played | 3 |
enlarged lymph | 3 |
acute abdomen | 3 |
new human | 3 |
molecular methods | 3 |
repair reaction | 3 |
en otras | 3 |
blood lymphocytes | 3 |
finding suggests | 3 |
incidental adenovirus | 3 |
common infectious | 3 |
inflammatory diseases | 3 |
optic neuropathy | 3 |
type cluster | 3 |
recent infection | 3 |
dermatological diseases | 3 |
toxic proteins | 3 |
kd findings | 3 |
severe complications | 3 |
disease acute | 3 |
retrospective series | 3 |
might actually | 3 |
intravenous pulse | 3 |
mild clinical | 3 |
elevated platelet | 3 |
classification criteria | 3 |
statistical power | 3 |
cases associated | 3 |
unclear whether | 3 |
hyperactivated immune | 3 |
stimulating factor | 3 |
commonly involved | 3 |
candidate gene | 3 |
cells control | 3 |
various tissues | 3 |
controlled studies | 3 |
new proteins | 3 |
first study | 3 |
anterior cervical | 3 |
produce il | 3 |
ammatory cytokines | 3 |
protein control | 3 |
one possible | 3 |
typical chest | 3 |
angiographically defi | 3 |
defi nition | 3 |
strong initial | 3 |
developing severe | 3 |
small aneurysms | 3 |
environmental changes | 3 |
complications occur | 3 |
pediatric respiratory | 3 |
one previous | 3 |
genital ulcers | 3 |
distinctive clinical | 3 |
regional laboratory | 3 |
occurred less | 3 |
combination therapy | 3 |
course group | 3 |
underlying mechanisms | 3 |
np swab | 3 |
plus ivig | 3 |
aneurysm rate | 3 |
untranslated region | 3 |
promoter polymorphisms | 3 |
porphyrin levels | 3 |
lower rates | 3 |
kg daily | 3 |
days associated | 3 |
microbial factors | 3 |
central asia | 3 |
anca associated | 3 |
may predispose | 3 |
uid pleocytosis | 3 |
study revealed | 3 |
paediatric acquired | 3 |
may occasionally | 3 |
normal distribution | 3 |
accessory protein | 3 |
receiving ivig | 3 |
commonly seen | 3 |
neutrophilic infi | 3 |
study hyperinflammatory | 3 |
ks may | 3 |
patients receiving | 3 |
showed normal | 3 |
highly variable | 3 |
mostly associated | 3 |
los labios | 3 |
risk score | 3 |
nerve conduction | 3 |
benign angiopathy | 3 |